New cellular immunotherapy approach shows promise for B-cell lymphoma

Off-the-shelf CAR-natural killer cells could expand accessibility, reduce cost of cell-based cancer therapies

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular immunotherapies less expensive and more accessible to patients. A phase 1 clinical trial found one such immunotherapy to be safe for patients with several types of B-cell lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy, but early data suggest this approach could offer a less toxic alternative to CAR-T cell therapies that are approved by the Food and Drug Administration to treat lymphoma.

The study, co-led by researchers at Washington University School of Medicine in St. Louis, was published Jan. 9 in The Lancet. The clinical trial was conducted at nine sites across the U.S. with Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine, enrolling the highest number of participants.

Like CAR-T cell therapy, in which immune cells called T cells are harvested from the patient and genetically modified to attack cancer cells, this new approach engineers a different type of immune cell called a natural killer (NK) cell. For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue — called induced pluripotent stem cells (iPSCs) — to make therapeutic CAR-NK cells. These new CAR-NK cells have features that allow them to be given to any patient without eliciting graft versus host diseases.

“The main difference between these CAR-NK cells and the FDA-approved CAR-T cell products lies in the ease of manufacturing,” said lead author Armin Ghobadi, MD, a professor of medicine and clinical director of the Center for Gene and Cellular Immunotherapy at the School of Medicine. “Currently, 10-20% of patients who need CAR-T cell therapy can’t access the treatment due to manufacturing failure or disease progression during manufacturing. Therapeutic CAR-NK cells produced from iPSCs address some of the key limitations of CAR-T cell therapies and could make cellular immunotherapy more accessible globally.”

Off-the-Shelf Immunotherapy

In cell-based immunotherapies, harnessing NK cells also is an attractive alternative to T cells, in part, because other clinical trials have shown NK cells administered therapeutically tend to cause fewer serious side effects than CAR-T cells do.

The CAR-NK cell product studied in this trial — called FT596 — was developed by Fate Therapeutics, which funded the trial. Compared with traditional CAR-T cell products, FT596 has several differences in design and manufacturing that could reduce cost, accelerate production and make this type of cellular immunotherapy available to more patients worldwide.

FT596 has features that allow the CAR-NK cells to target the cancer in two different ways to avoid tumor resistance, compared with standard CAR-T cell therapy, which only targets the cancer cells in one way.

CAR-T cell products are made by harvesting T cells from donors or directly from the patient, shipping them to a manufacturing facility, genetically modifying them, expanding their numbers and then shipping them back to be administered to the patient in a process that takes three to five weeks. Induced pluripotent stem cell-derived CAR-NK cell products such as FT596 eliminate the harvesting, initial shipping, and patient-specific manufacturing as it is off-the-shelf and is available right away for broad patient access.

These therapeutic CAR-NK cells are made from induced pluripotent stem cells derived from healthy donor fibroblast cell lines with centralized manufacturing of a large number of doses per manufacturing run. These CAR-NK cells can be prepared ahead of time, stored and shipped to a patient’s doctor when needed or in advance. This is similar to off-the-shelf medicines in a pharmacy, potentially making iPSC-derived CAR-NK cell therapies more accessible to patients in places where health-care services don’t have the infrastructure to collect, freeze and ship donor cells, according to the investigators. The CAR-NK cell production process also avoids the variability seen in cell therapy products when the starting cells originate from a unique donor each time.

Promising Results of CAR-NK Immunotherapy

To assess the safety of off-the-shelf cellular immunotherapy, the study administered the CAR-NK cells to 86 patients with hard-to-treat B-cell lymphomas. On average, patients had already received four lines of therapy, including FDA-approved CAR-T cell therapy for 33 of the patients. Their cancers either had not responded to those treatments initially or had later returned. Patients with lymphoma whose disease has returned after several lines of therapy have a very poor prognosis, with most succumbing to the disease within a few months.

The trial investigated escalating doses of the CAR-NK cells and found that patients tolerated even the highest dose given in this trial. The investigators tested these CAR-NK cells alone in 18 patients and for the remainder in combination with rituximab, a monoclonal antibody that helps further target the CAR-NK cells to lymphoma cells.

A total of 10 study participants experienced low-grade cytokine release syndrome, a side effect of immunotherapy that was managed with additional treatments. None of the patients experienced neurotoxicity, which can be a serious complication for some patients who receive CAR-T cell therapy. These results suggest CAR-NK cells could be safely administered in an outpatient setting.

Patients with follicular lymphoma, a slow-growing form of the blood cancer, responded most to the experimental therapy. All of them responded at least partially, and 85% experienced a complete response, meaning their cancer could no longer be detected after treatment with CAR-NK cells. This response continued for an average of almost 17 months after treatment. Among 20 patients with relapsed or progressed disease after standard CAR-T cell therapy who then received CAR-NK cell therapy plus rituximab, 45% responded with 30% achieving complete remission.

“In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity,” Ghobadi said. “For patients with large B-cell lymphoma who undergo FDA-approved CAR-T cell therapy, approximately 60% experience a relapse. These patients have very limited treatment options, and most survive only a few months. This study demonstrates that nearly half of these patients could achieve another complete or partial remission with FT596, representing a significant improvement.”

The apparent safety of the new approach also makes it appealing for investigating the potential of CAR-NK cells in treating solid tumors and autoimmune diseases.

# # #

Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, Bachier C, Diefenbach CS, Wong C, Bickers C, Wong L, Patel D, Goodridge J, Denholt M, Valamehr B, Elstrom RL, Strati P. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. The Lancet. Jan. 9, 2025.

This work was funded by Fate Therapeutics, which developed and manufactured FT596. The funder had a role in study design, data collection, data analysis, interpretation and the writing of the report.

For Your Health: Making time for our health during the holidays

For Your Health Graphic 2020








We’re entering one of those special times of the year — the winter holidays.

It’s a concentrated few weeks that give many of us the chance to spend extra time with friends, family and colleagues, celebrating the past year while looking toward the possibilities of the next.

And though the season’s colder weather and shorter days may make us feel like hibernating, we often find ourselves surprisingly busy. Kids are out of school. Work may have end-of-year deadlines, and there are preparations for holiday gatherings and family visits.

It’s a season to look forward to — and one that can also make it harder to look after our own health and well-being. But taking time for ourselves is still an important goal, no matter how busy we are. It’s not only good for our long-term health, it can also give us the physical and mental energy to enjoy all the holidays have to offer.

Try these four tips to help your holiday health:

1.) Focus on sleep.

It’s easy to cut back on healthy sleep when we feel a time crunch, but we really shouldn’t. Sleep is important for both our daily and long-term health, so we should do what we can to get the seven or more hours a night that most adults need. Of course, getting a healthy amount of sleep can be difficult no matter the time of year. So, don’t stress about it, but do what you can to find sleep success. Try to give yourself the time to sleep; don’t overschedule your nights or early mornings, which can easily happen during the holidays. Putting away electronics and avoiding large meals near bedtime can also help, as can keeping to a regular sleep and wake-up time.

2.) Get out for a walk — or other activity.

Along with sleep, this is another one that’s easy to skip when our days get busy. But making time to go for a walk or take a gym class has amazing benefits — providing a boost to energy and mood, and even helping with better sleep. It’s not always easy to get started, especially in winter, but those first few minutes of an activity are often the hardest; once past those, the rest usually comes easier. And, if you’re heading outside, be sure to be prepared for the weather, and go with a friend.

3.) Remember to choose healthy foods — mostly.

The holidays are a time to celebrate, and that can mean enjoying food without worrying about how healthy it is. It’s good, though, to not totally do away with our healthy eating habits this season. Still try to take an overall healthy approach to eating that focuses on fruits, vegetables and whole grains, and is low in red and processed meat. At special meals and other gatherings, choose what you enjoy but try to balance less-healthy, higher-calorie foods with healthier choices.

4.) Relieve stress in healthy ways.

As great as the holidays can be, they can also, as we know, be stressful. And that makes it important to have healthy ways to deal with moments of stress. Walking and similar activities are really good for this. So, too, are stretching, yoga and breathing exercises. Taking some time alone can be helpful, finding a quiet place to read or stream that movie you’ve been wanting to see. Spending time with friends can also provide support. While alcohol may be part of many holiday celebrations, choose healthier options for dealing with the stress of the season. And if you or anyone you know is in a mental health crisis, call 988 — the Suicide and Crisis Lifeline.

These can feel like simple things, and in many ways they are. But during such a busy season, it can be good to focus on some of the basics. And the benefits of keeping up with even small, healthy steps are real — in our daily lives and the years ahead.

That’s a great gift. Happy Holidays and Happy New Year.

Research Reveals How Fructose in Diet Enhances Tumor Growth

Fructose consumption has increased considerably over the past five decades, largely due to the widespread use of high-fructose corn syrup as a sweetener in beverages and ultra-processed foods. New research from Washington University in St. Louis shows that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer and cervical cancer. However, fructose does not directly fuel tumors, according to the study published Dec. 4 in the journal Nature.

Instead, Washington University scientists discovered that the liver converts fructose into usable nutrients for cancer cells, a compelling finding that could open up new avenues for care and treatment of many different types of cancer.

Gary Patti, PhD
Gary Patti, PhD

“The idea that you can tackle cancer with diet is intriguing,” said Gary Patti, PhD, the Michael and Tana Powell Professor of Chemistry in Arts & Sciences and a professor of genetics and of medicine at the School of Medicine, all at Washington University. Patti also is a research member of Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine.

“When we think about tumors, we tend to focus on what dietary components they consume directly. You put something in your body, and then you imagine that the tumor takes it up,” Patti said. “But humans are complex. What you put in your body can be consumed by healthy tissue and then converted into something else that tumors use.”

Ronald Fowle Grider
Ronald Fowle-Grider, PhD

“Our initial expectation was that tumor cells metabolize fructose just like glucose, directly utilizing its atoms to build new cellular components such as DNA. We were surprised that fructose was barely metabolized in the tumor types we tested,” said the study’s first author, Ronald Fowle-Grider, PhD, a postdoctoral fellow in Patti’s lab. “We quickly learned that the tumor cells alone don’t tell the whole story. Equally important is the liver, which transforms fructose into nutrients that the tumors can use.”

Using metabolomics — a method of profiling small molecules as they move through cells and across different tissues in the body — the researchers concluded that one way in which high levels of fructose consumption promote tumor growth is by increasing the availability of circulating lipids in the blood. These lipids are building blocks for the cell membrane, and cancer cells need them to grow.

“We looked at numerous different cancers in various tissues throughout the body, and they all followed the same mechanism,” Patti said.

The Corn Syrup Era

Scientists have long recognized that cancer cells have a strong affinity for glucose, a simple sugar that is the body’s preferred carbohydrate-based energy source.

In terms of its chemical structure, fructose is similar to glucose. They are both common types of sugar, with the same chemical formula, but they differ in how the body metabolizes them. Glucose is processed throughout the whole body, while fructose is almost entirely metabolized by the small intestine and liver.

Both sugars are found naturally in fruits, vegetables, dairy products and grains. They are also added as sweeteners in many processed foods. Fructose, in particular, has penetrated the American diet over the last few decades. It is favored by the food industry because it is sweeter than glucose.

Prior to the 1960s, people consumed relatively little fructose compared with today’s numbers. A century ago, an average person consumed just 5-10 pounds of fructose per year. To put it in familiar terms, that is roughly equal to the weight of a gallon of milk. In the 21st century, that number has increased to be as high as the equivalent of 15 gallons of milk.

“If you go through your pantry and look for the items that contain high-fructose corn syrup, which is the most common form of fructose, it is pretty astonishing,” said Patti, who also is a research member of the Center for Human Nutrition at the School of Medicine. “Almost everything has it. It’s not just candy and cake, but also foods such as pasta sauce, salad dressing and ketchup,” he said. “Unless you actively seek to avoid it, it’s probably part of your diet.”

Cancer’s Appetite for Fructose

Given the rapid rise in the consumption of dietary fructose over recent decades, the Washington University researchers wanted to know more about how fructose impacts the growth of tumors.

Patti and Fowle-Grider began their investigation by feeding tumor-bearing animals a diet rich in fructose, then measuring how quickly their tumors grew. The researchers found that added fructose promoted tumor growth without changing body weight, fasting glucose or fasting insulin levels.

“We were surprised to see that it had a rather dramatic impact. In some cases, the growth rate of the tumors accelerated by two-fold or even higher,” Patti said. “Eating a lot of fructose was clearly very bad for the progression of these tumors.”

But the next step in their experiments initially stumped them. When Fowle-Grider attempted to repeat a version of this test by feeding fructose to cancer cells isolated in a dish, the cells did not respond. “In most cases they grew almost as slowly as if we gave them no sugar at all,” Patti said.

So, Patti and Fowle-Grider went back to looking at changes in the small molecules in the blood of animals fed high-fructose diets. Using metabolomics, they identified elevated levels of a variety of lipid species, including lysophosphatidylcholines (LPCs). Additional dish tests showed that liver cells that were fed fructose release LPCs.

“Interestingly, the cancer cells themselves were unable to use fructose readily as a nutrient because they do not express the right biochemical machinery,” Patti said. “Liver cells do. This allows them to convert fructose into LPCs, which they can secrete to feed tumors.”

A defining characteristic of cancer is uncontrolled proliferation of malignant cells. Each time a cell divides, it must replicate its contents, including membranes. This requires a substantial amount of lipids. While lipids can be synthesized from scratch, it is much easier for cancer cells to simply take lipids up from their surrounding environment.

“Over the past few years, it’s become clear that many cancer cells prefer to take up lipids rather than make them,” Patti noted. “The complication is that most lipids are insoluble in blood and require rather complex transport mechanisms. LPCs are unique. They might provide the most effective and efficient way to support tumor growth.”

Avoiding Fructose

Interestingly, over the same period of time when human fructose consumption has surged, a number of cancers have become increasingly more prevalent among people under the age of 50. This raises the question of whether the trends are linked. With $25 million in support from Cancer Grand Challenges, Patti recently teamed up with Yin Cao, ScD, MPH, an associate professor of surgery at the School of Medicine and a fellow Siteman research member, and other investigators from around the world, none of whom were involved in this study, to investigate possible connections.

“It will be exciting to better understand how dietary fructose influences cancer incidence. But one take-home message from this current study is that if you are unfortunate enough to have cancer, then you probably want to think about avoiding fructose. Sadly, that is easier said than done,” Patti said.

Aside from dietary intervention, the study authors said that this research could help us develop a way to prevent fructose from driving tumor growth therapeutically, using drugs.

“An implication of these findings is that we do not have to limit ourselves to therapeutics that only target disease cells,” Patti said. “Rather, we can think about targeting the metabolism of healthy cells to treat cancer. This has worked with mice in our study, but we would like to take advantage of our observations and try to improve the lives of patients.”

The study authors are working with clinical partners at Washington University School of Medicine to explore a clinical trial related to fructose in the diet.

Analyzing multiple mammograms improves breast cancer risk prediction

AI method spots subtle changes over time, enhances accuracy of determining 5-year risk

A new study from Washington University School of Medicine in St. Louis describes an innovative method of analyzing mammograms that significantly improves the accuracy of predicting the risk of breast cancer development over the following five years. Using up to three years of previous mammograms, the new method identified individuals at high risk of developing breast cancer 2.3 times more accurately than the standard method, which is based on questionnaires assessing clinical risk factors alone, such as age, race and family history of breast cancer.

The study is published Dec. 5 in JCO Clinical Cancer Informatics.

“We are seeking ways to improve early detection, since that increases the chances of successful treatment,” said senior author Graham A. Colditz, MD, DrPH, associate director, prevention and control, of Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine, and the Niess-Gain Professor of Surgery. “This improved prediction of risk also may help research surrounding prevention, so that we can find better ways for women who fall into the high-risk category to lower their five-year risk of developing breast cancer.”

This risk-prediction method builds on past research led by Colditz and lead author Shu (Joy) Jiang, PhD, a statistician, data scientist and associate professor of surgery in the Division of Public Health Sciences at the School of Medicine. The researchers showed that prior mammograms hold a wealth of information on early signs of breast cancer development that can’t be perceived even by a well-trained human eye. This information includes subtle changes over time in breast density, which is a measure of the relative amounts of fibrous versus fatty tissue in the breasts.

For the new study, the team built an algorithm based on artificial intelligence that can discern subtle differences in mammograms and help identify those women at highest risk of developing a new breast tumor over a specific timeframe. In addition to breast density, their machine-learning tool considers changes in other patterns in the images, including in texture, calcification and asymmetry within the breasts.

“Our new method is able to detect subtle changes over time in repeated mammogram images that are not visible to the eye,” said Jiang, yet these changes hold rich information that can help identify high-risk individuals.

At the moment, risk-reduction options are limited and can include drugs such as tamoxifen that lower risk but may have unwanted side effects. Most of the time, women at high risk are offered more frequent screening or the option of adding another imaging method, such as an MRI, to try to identify cancer as early as possible.

“Today, we don’t have a way to know who is likely to develop breast cancer in the future based on their mammogram images,” said co-author Debbie L. Bennett, MD, an associate professor of radiology and chief of breast imaging for the Mallinckrodt Institute of Radiology at the School of Medicine. “What’s so exciting about this research is that it indicates that it is possible to glean this information from current and prior mammograms using this algorithm. The prediction is never going to be perfect, but this study suggests the new algorithm is much better than our current methods.”

AI Improves Prediction of Breast Cancer Development

The researchers trained their machine-learning algorithm on the mammograms of more than 10,000 women who received breast cancer screenings through Siteman Cancer Center from 2008 – 2012. These individuals were followed through 2020, and in that time 478 were diagnosed with breast cancer.

The researchers then applied their method to predict breast cancer risk in a separate set of patients — more than 18,000 women who received mammograms through Emory University in the Atlanta area from 2013 – 2020. Subsequently, 332 women were diagnosed with breast cancer during the follow-up period, which ended in 2020.

According to the new prediction model, women in the high-risk group were 21 times more likely to be diagnosed with breast cancer over the following five years than were those in the lowest-risk group. In the high-risk group, 53 out of every 1,000 women screened developed breast cancer over the next five years. In contrast, in the low-risk group, 2.6 women per 1,000 screened developed breast cancer over the following five years. Under the old questionnaire-based methods, only 23 women per 1,000 screened were correctly classified in the high-risk group, providing evidence that the old method, in this case, missed 30 breast cancer cases that the new method found.

The mammograms were conducted at academic medical centers and community clinics, demonstrating that the accuracy of the method holds up in diverse settings. Importantly, the algorithm was built with robust representation of Black women, who are usually underrepresented in development of breast cancer risk models. The accuracy for predicting risk held up across racial groups. Of the women screened through Siteman, most were white, and 27% were Black. Of those screened through Emory, 42% were Black.

In ongoing work, the researchers are testing the algorithm in women of diverse racial and ethnic backgrounds, including those of Asian, southeast Asian and Native American descent, to help ensure that the method is equally accurate for everyone.

The researchers are working with Washington University’s Office of Technology Management toward patents and licensing on the new method with the goal of making it broadly available anywhere screening mammograms are provided. Colditz and Jiang also are working toward founding a start-up company around this technology.

Siteman Cancer Center’s new outpatient building named in honor of Gary C. Werths

Generous gift to WashU Medicine supports cancer research, medical student scholarships

In recognition of a transformative commitment to Washington University School of Medicine in St. Louis from St. Louisan Richard Frimel and his late husband, Gary C. Werths, Siteman Cancer Center’s new building for outpatient care will be named the Gary C. Werths Building. The historic pledge will fund groundbreaking cancer research and medical student scholarships to support aspiring physicians.

The nine-story building opened in September on the Washington University Medical Campus and exemplifies the collaborative strength of BJC HealthCare and WashU Medicine in providing innovative cancer care. Patients receive the most advanced, lifesaving therapies informed by the latest research discoveries, many of them made by WashU Medicine faculty who are leaders in their fields.

“We are honored to name Siteman’s new building after Gary, forever linking his name with world-class, compassionate cancer care,” Chancellor Andrew D. Martin said. “Gary and Richard’s extraordinary commitment will advance WashU Medicine’s innovative cancer research and provide enduring scholarship support for future generations of physicians. Their philanthropy offers hope to cancer patients and their families and will help alleviate the financial burden of attending medical school for students aspiring to become physicians.”

The pledge is the largest single philanthropic investment in Siteman Cancer Center since Alvin J. and Ruth Siteman’s founding gift 25 years ago.

Siteman – based at Barnes-Jewish Hospital and WashU Medicine – is the only National Cancer Institute-designated Comprehensive Cancer Center in Missouri and southern Illinois and draws patients from across the U.S. and beyond who seek access to the latest treatments and technologies as well as innovative clinical trials.

“At WashU Medicine, we fully recognize that investing in pioneering research is essential to advancing cancer care and improving outcomes for patients,” said David H. Perlmutter, MD, the George and Carol Bauer Dean of WashU Medicine, executive vice chancellor for medical affairs and the Spencer T. and Ann W. Olin Distinguished Professor. “Gary Werths’ legacy will live on through the excellent patient care delivered every day in this beautiful new building and the scholarships that will change the future for generations of medical students.”

The Gary C. Werths Building is thoughtfully designed, with cancer patients’ needs at its core. An innovative model of care enables many patients to see a multidisciplinary team of WashU Medicine cancer specialists at Siteman and receive chemotherapy and other services in collaboration with BJC caregivers, all coordinated during a single visit. This patient-centered approach focuses on their comfort and convenience and reduces the need to return for multiple appointments.

Frimel and Werths’ commitment will advance discoveries by WashU Medicine researchers at Siteman that shape the future of cancer diagnostics and therapeutics and redefine excellence in cancer research and patient care. It will bolster efforts to better understand cancer, pioneer new therapies, conduct leading-edge clinical trials and enhance patient care.

Their pledge also will support medical student scholarships in perpetuity. Such support will enable WashU Medicine to attract the best and brightest students who can pursue their dreams of becoming physicians without having to take on overwhelming financial debt.

Additionally, the gift will benefit cancer patients in St. Louis and beyond.

“Much of our research and medical training emphasizes the importance of community outreach and cancer prevention,” said Timothy J. Eberlein, MD, director of Siteman Cancer Center, the Spencer T. and Ann W. Olin Distinguished Professor and senior associate dean for cancer programs at WashU Medicine and BJC HealthCare. “This transformational gift will help assure that Siteman continues to provide the most innovative and impactful treatments to our patients in the most supportive, compassionate environment possible.”

Dedicated to giving back

Werths Building Image 2
Artwork in the Gary C. Werths Cancer Building at Siteman Cancer Center — based at Barnes-Jewish Hospital and WashU Medicine — reflects Werths’ deep love of art and his belief in the positive and comforting effects of art.

Werths died from Alzheimer’s disease in February 2021 at age 83. He achieved prominence within the St. Louis and international art communities as owner of Gary’s Antiques & Imports in the Central West End neighborhood that borders the Washington University Medical Campus. Werths and Frimel also were business partners, working to supply fine art to decorators, designers and architects throughout the Midwest. An avid art collector and travel enthusiast, Werths served as a trustee of the Saint Louis Art Museum, a charter member of the Central West End Savings & Loan and a board member of Harvest Bank in Dubuque, Iowa.

Through his estate, Werths previously made a gift to WashU that was designated for undergraduate scholarships and Alzheimer’s disease research.

“Gary referred to WashU Medicine and Barnes-Jewish Hospital as our best neighbors,” Frimel said. “He always had a fondness and deep respect for the physicians and caregivers on the Medical Campus. He believed in them and would be proud to support research to improve cancer care and treatment, and scholarships to support future physicians on their journeys to becoming doctors.”

Image of two men, Richard Frimel and the late Gary C. Werths, wearing tuxedos with arms around each other
In honor of the generous contributions to cancer research and medication education from Richard Frimel (left) and the late Gary C. Werths (right), a new building at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, is named the Gary C. Werths Building.

Frimel noted that Werths would have loved the design of the new building named in his honor.

“It’s fabulous on many levels,” Frimel said. “It’s contemporary, and the layout is wonderful. The expanse of windows makes the building light and airy. From one direction, you look out at the whole Central West End, and from the other direction, you can see the Arch.”

Through his business, Werths provided art to decorate buildings and physician offices. Frimel said Werths believed art could have a positive effect and act as a source of comfort — a belief carried forward in the inspirational art in his namesake building. “The art is colorful, bright and cheerful,” Frimel said. “It’s just wonderful.”

Probiotic delivers anticancer drug to the gut

Oral immunotherapy shrinks gastrointestinal tumors in mouse study

Immunotherapy is a promising treatment that recruits the immune system to help fight cancer, but it has had limited success in gastrointestinal cancers. Now, researchers at Washington University School of Medicine in St. Louis have engineered a probiotic that delivers immunotherapy directly to the gut to shrink tumors in mice, offering a potentially promising oral drug for hard-to-reach cancers.

The probiotic cancer treatment, described Nov. 20 in the journal Cell Chemical Biology, establishes a customizable drug delivery system that can be modified to potentially treat other gut diseases.

“Gastrointestinal cancers are difficult to treat, in part because of their location,” said Gautam Dantas, PhD, the study’s senior author and the Conan Professor of Laboratory and Genomic Medicine in the Department of Pathology & Immunology at WashU Medicine. “We have engineered a yeast-based probiotic that delivers immunotherapy directly to the tumor site. Our hope is that one day the probiotic could be added to the arsenal of therapies to help shrink tumors in people.”

Gastrointestinal cancers, including stomach, liver, esophageal, pancreatic and colorectal cancers, represent more than one-quarter of all cancers. More than 5 million people are living with such cancers – a number that is growing – and 3.7 million die worldwide each year. Late-stage detection, due in part by anatomical challenges that hinder imaging and sampling of the long and complex gastrointestinal system composed of various organs and tissues, has contributed to the high mortality rate. Patients may require a combination therapy regime, including surgery, chemotherapy, radiation therapy and immunotherapy, among others.

Although immunotherapy drugs for gastrointestinal cancers are available, they are delivered intravenously and often exhibit limited effectiveness. Safe doses of immunotherapy may not be sufficient to reach the tumor site and be effective, Dantas explained. Oral immunotherapy drugs could directly target hard-to-reach gastrointestinal cancers, but such protein-based treatments degrade in the gut’s harsh environment before reaching the tumors. Probiotics – bacteria and yeast – can withstand stomach acid and digesting enzymes, offering a potentially promising strategy for safely transporting protein-based drugs that otherwise would get chewed up.

Co-first author Olivia Rebeck, who conducted the experiments when she was a graduate student in the Dantas lab with postdoctoral scholars Miranda Wallace, PhD, and Jerome Prusa, PhD, used a yeast strain to deliver immunotherapy to the gut. The yeast – Saccharomyces cerevisiae var. boulardii – is a commonly used and safe probiotic. Unlike bacteria, the microorganism is less likely to exchange genetic material with other microbes and doesn’t take up residence in the gastrointestinal tract where it could potentially disrupt microbial communities. Its natural anticancer properties, found to inhibit some types of cancer cells in a dish, potentially offer an additional benefit.

The researchers engineered yeast to act as single-celled drug factories and produce immune checkpoint inhibitors – anticancer drugs that alert immune cells to the presence of cancer cells. Tumors sabotage the process that the body’s healthy cells use to avoid immune recognition and subsequent attack, allowing cancer to hide from the immune system. The researchers found the yeast-based probiotic made and secreted the drug that releases the brake on the immune system, allowing it to fight tumors.

The researchers gave mice with colorectal cancer the drug-making probiotic or an intravenous injection of the immunotherapy drug. They found fewer tumors in mice receiving the probiotic compared with mice given immunotherapy drugs systemically.

The researchers have filed two patents – with help from the Office of Technology Management at WashU – related to the engineered probiotic.

Using yeast as a delivery system can be adapted for other gastrointestinal diseases. The researchers are currently working on modifying the system to help combat Clostridioides difficile, commonly referred to as C. diff, a bacterium that can cause diarrhea and colitis, among other symptoms. Delivering therapies that directly target the bug or its toxins could potentially replace the need for antibiotics that also harm beneficial gut microbes.

# # #

Rebeck ON, WallaceMJ, Prusa J, Ning J, Evbuomwan EM, Rengarajan S, Habimana-Griffin L, Kwak S, Zahrah D, Tung J, Liao J, Mahmud B, Fishbein SRS, Ramirez Tovar ES, Mehta R, Wang B, Gorelik MG, Helmink BA, Dantas G. A yeast-based oral therapeutic platform for delivery of immune checkpoint inhibitors reduces intestinal tumor burden. Cell Chemical Biology. Nov 20, 2024.
DOI: 10.1016/j.chembiol.2024.10.013

This study was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), grant numbers R01AI155893 and K99AI17674; the National Center for Complementary and Integrative Health of the National Institutes of Health (NIH), grant numbers R01AT00974 and K99AT012651; the National Institute of General Medicine Scientists of the NIH, grant numbers T32GM007067, R25GM103757 and 5T34GM141639; the National Cancer Institute of the NIH, grant number T32CA11327; the National Institute of Child Health and Human Development of the NIH, grant number T32HD004010; the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, grant number T32DK077653. Radiological Society of North America, grant number RR2336; the Washington University/Mallinckrodt/Siteman Kornfeld PSTP Post-Bac Scholars Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Dantas G, Helmink BA, Rebeck ON, WallaceMJ, Prusa J, and Kwak S are inventors on a patent application related to the yeast-based ICI delivery system. Dantas G and Kwak S are inventors on another patent related to the use of engineered microbes as therapeutic agents (Publication #: WO/2020/061389, filed 20 Sept. 2019).

Vaccine Shows Promise Against Aggressive Breast Cancer

Clinical trial targeted recurrence of hard-to-treat triple-negative breast cancer

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by Washington University researchers, the trial is the first to report results for this type of vaccine — known as a neoantigen DNA vaccine — for breast cancer patients.

The study, which found the vaccine to be well-tolerated and to stimulate the immune system, is available Nov. 14 in the journal Genome Medicine.

The phase I clinical trial — conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine — involved 18 patients diagnosed with triple-negative breast cancer that was not metastatic, meaning it had not spread to other organs. Each patient received the standard of care and three doses of a personalized vaccine tailored to home in on key mutations in their specific tumor and train immune cells to recognize and attack any cells bearing these mutations.

Following treatment, 14 of 18 patients showed immune responses to the vaccine and, after three years, 16 patients remained cancer-free. While the early-stage trial was designed to evaluate safety of the vaccine and did not include a control group to determine efficacy, the researchers analyzed historical data from patients with triple-negative breast cancer treated with the standard of care only. In that group, on average, about half of patients remained cancer-free at three years post-treatment.

“These results were better than we expected,” said senior author William E. Gillanders, MD, the Mary Culver Distinguished Professor of Surgery at the School of Medicine who treats patients at Siteman. “Obviously, it’s not a perfect comparison, and we acknowledge the limitations of this type of analysis, but we are continuing to pursue this vaccine strategy and have ongoing randomized controlled trials that do make a direct comparison between the standard of care plus a vaccine, versus standard of care alone. We are encouraged by what we’re seeing with these patients so far.”

Triple-negative breast cancer is an aggressive tumor type that grows even in the absence of the hormonal fuel that drives growth of other types of breast cancer. To date, triple-negative breast cancer has no targeted therapies and is usually treated with traditional approaches that include surgery, chemotherapy and radiation therapy. For reasons that scientists are still investigating, this tumor tends to be more common among African American patients diagnosed with breast cancer. In this trial, one-third of the participants (six of 18) were African American.

For this trial, patients with triple-negative breast cancer who still had evidence of a tumor remaining after a first round of chemotherapy were eligible to participate. Such patients are at high risk of cancer recurrence even after the remaining tumor is surgically removed. After surgical removal, the research team analyzed and compared the tumor tissue with the same patient’s healthy tissue to find unique genetic mutations in the cancer cells. Such mutations in a patient’s cancer cells alter the proteins only in the tumor, making it possible to train the immune system to go after the altered proteins and leave healthy tissues alone.

Using software they designed, the researchers selected altered proteins — called neoantigens — that were made by the patients’ tumors and that were identified as most likely to trigger a strong immune response. On average, each patient’s vaccine contained 11 neoantigens (ranging from a minimum of four to a maximum of 20) specific to their tumor.

The software development was led by computational biologists Obi Griffith, PhD, a professor of medicine, and Malachi Griffith, PhD, an associate professor of medicine, both in the Division of Oncology at the School of Medicine. A related paper published simultaneously in the same journal describes the software tools they developed. One of their goals is to make these computational resources widely accessible to cancer researchers and clinicians worldwide.

“We hope to promote the use of this software for the design of cancer vaccines,” Malachi Griffith said. “These are complex algorithms, but in general, the software takes in a list of mutations and interprets them in the context of their potential to be good neoantigen candidates. The tools rank the possible neoantigens based on our current knowledge of what matters in stimulating the immune system to attack cancer cells. These software tools were developed with support from the National Cancer Institute, and they have an open license that makes them broadly available for both academic and commercial uses.”

Several studies of cancer vaccines are ongoing at Siteman. Vaccines for all of these trials are made in a Washington University School of Medicine facility that meets the good manufacturing practice (GMP) requirements set by the Food and Drug Administration. In some of the vaccine clinical trials for breast cancer patients, personalized vaccines are being investigated in combination with immunotherapies called checkpoint inhibitors that boost the action of T cells.

“We are excited about the promise of these neoantigen vaccines,” Gillanders said. “We are hopeful that we will be able to bring more and more of this type of vaccine technology to our patients and help improve treatment outcomes in patients with aggressive cancers.”

Learn more about all breast cancer clinical trials available at Siteman.

________________________________________________________________________________________

Zhang X, Goedegebuure P, Chen MY, Mishra R, Zhang F, Yu YY, Singhal K, Li L, Gao F, Myers NB, Vickery T, Hundal J, McLellan MD, Sturmoski MA, Kim SW, Chen I, Davidson JT, Sankpal NV, Myles S, Suresh R, Ma CX, Foluso A, Wang-Gillam A, Davies S, Hagemann IS, Mardis ER, Griffith O, Griffith M, Miller CA, Hansen TH, Fleming TP, Schreiber RD, Gillanders WE. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Medicine. Nov. 14, 2024.

This work was supported by Susan G. Komen for the Cure, grant number KG111025; the Alvin J. Siteman Cancer Center/Siteman Investment Program grant 4035; the National Institutes of Health (NIH), grant numbers R01 CA240983, P30‐CA091842, U01 CA248235 and T32 CA009621; the Foundation for Barnes‐Jewish Hospital; and the Centene Corporation contract P19‐00559 B101 for the Washington University‐Centene ARCH Personalized Medicine Initiative.

Xia H, Hoang MH, Schmidt E, Kiwala S, McMichael J, Skidmore ZL, Fisk B, Song JJ, Hundal J, Mooney T, Walker JR, Goedegebuure SP, Miller CA, Gillanders WE, Griffith OL, Griffith M. pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection. Genome Medicine. Nov. 14, 2024.

This work was supported by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), grant number R00HG007940; the National Cancer Institute (NCI) of the NIH, grant number U01CA248235; the V Foundation for Cancer Research, award number V2018-007; the Centene Corporation contract P19-00559 for the Washington University-Centene ARCH Personalized Medicine Initiative; and the Goldberg Family Foundation.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.